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Abstract 
 
OBJECTIVE : 
To determine the role of miR-21 on the homeostasis of monocyte subsets and on atherosclerosis 
development in ApoE-/- mice. 
APPROACH and RESULTS : 
In ApoE-/- mice, miR-21 expression was increased in circulating Ly-6Clo monocytes (NC-Mo) in 
comparison to Ly-6Chi monocytes. The absence of miR-21 significantly altered the survival and 
number of circulating NC-Mo in ApoE-/- mice. In the early stages of atherosclerosis, the absence of 
miR-21 limited lesion development both in the aortic sinus (by almost 30%) and in the aorta (by 
almost 50%). This was associated with less monocyte availability in circulation and increased 
apoptosis of local macrophages in plaques. At later stages of atherosclerosis, lesion size in the 
aortic root was similar in ApoE-/- and ApoE-/-miR-21-/- mice, but plaques showed a less stable 
phenotype (larger necrotic cores) in the latter. The loss of protection in advanced stages was 
most likely due to excessive inflammatory apoptosis related to an impairment of local efficient 
efferocytosis. 
CONCLUSION : Gene deletion of miR-21 in ApoE-/- mice alters NC-Mo homeostasis and contribute 
to limit early-stage atherosclerosis. 
 
 
Non standard Abbreviations and acronyms: 
C-Mo : Ly-6Chi classical monocytes 
NC-Mo : Ly-6Clo nonclassical monocytes 
ApoE : Apolipoprotein E 
Ldlr : Low density lipoprotein receptor 
BMT: Bone marrow transplantation 
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Introduction 
Monocytes are critical to the development of atherosclerosis and inhibition of monocyte 
development or trafficking strongly impairs atherosclerotic lesion formation1-3. Monocyte-
derived macrophages accumulate in the plaque and transform into lipid-loaded foam cells, often 
committed to death. In early plaques, when phagocytic clearance of apoptotic cells (efferocytosis) 
is optimal, apoptosis is beneficial and helps limit lesion development. In the later stages of 
atherosclerosis, when efferocytosis is deregulated, necrosis secondary to apoptosis promotes 
plaque inflammation and lesion progression4. Currently, several types of monocyte subsets have 
been described and are thought to have divergent functions. In mice, classical Ly-6ChiCCR2+ 
monocytes (C-Mo) migrate to sites of injury where they differentiate into inflammatory 
macrophages. C-Mo dominate hypercholesterolemia-associated monocytosis and macrophage 
accumulation in the plaque5. In contrast, Ly-6CloCX3CR1hi non-classical monocytes (NC-Mo) 
exhibit a unique ability to patrol the vasculature and remove damaged cells and debris6. In 
atherosclerosis, the exact role of NC-Mo is not fully understood. Recent studies suggested that 
their patrolling along the vascular wall limit vascular inflammation and early atherogenesis7, 8. 
The transcription factor NR4A1 is absolutely required for NC-Mo development, and mice 
deficient for NR4A1 lack NC-Mo and accumulate M1-like macrophages in the plaque, favoring 
accelerated atherosclerosis9. However, in another study, the lack of NR4A1 had no impact on 
macrophage polarization and did not change atherosclerosis10. More recently, E2 domain-
deficient Ldlr-/- mice which lack Ly6Clow monocytes but retain Nr4a1 gene expression in 
macrophages were shown to have accelerated atherosclerosis8. The chemokine receptor CX3CR1 
also contribute to NC-Mo survival and the absence of CX3CR1, which impairs NC-Mo number in 
blood of ApoE-/- or Ldlr-/- mice, protected mice against atherosclerosis11, 12. The discrepancy 
between these studies highlights the need to identify key molecular mechanisms underlying 
maintenance of monocyte subsets. MicroRNAs are well-conserved, short non-coding RNAs, 
known to play major roles in most biological processes by influencing the stability and 
translation of mRNAs13. 
miR-21 plays important roles in leukocyte function, driving both cell polarization and survival, 
particularly during inflammatory conditions14-16. miR-21 has been linked to several 
cardiovascular diseases and highly correlates with the evolution of multiple cancers. A recent 
study reported that deletion of miR-21 in the hematopoietic compartment of LDLr-/- mice on high 
fat diet (HFD) accelerated the development of advanced atherosclerosis in part through 
accumulation of inflammatory macrophages and defective efferocytosis17. Here, we aimed to 
investigate the role of miR-21 on homeostasis of monocytes in ApoE-/- mice and its effect in early 
and advanced stages of atherosclerosis. 
 
Materials and Methods 
All supporting data are available within the article [and its online supplementary files]. 
 
Animals 
Experiments were conducted according to the guidelines formulated by the European 
Community for experimental animal use (L358-86/609EEC) and were approved by the Ethical 
Committee of INSERM and the French Ministry of Agriculture (agreement A75-15-32). 
miR-21-/- mice were obtained from Pr. Marc E. Rothenberg (Cincinnati Children's Hospital 
Medical Center). ApoE-/- mice were from Jackson laboratories and are maintained in our animal 
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facility. ApoE-/- miR21-/- mice were generated in our facility, and littermates ApoE-/-miR21+/+ 
(called ApoE-/-) of the same age and sex were used as control. Because sexual dimorphisms have 
been reported in atherosclerosis studies18, particularly when comparing early and advanced 
atherosclerosis19, we used one gender to minimize the number of mice used in the study and 
chose males as in Canfran-Duque et al17 and Jin et al20. B6-Ly5.1/Cr mouse, which carry the allele 
CD45.1 were purchased from Charles River and crossed to ApoE-/- mice to generate ApoE-/- CD45.1 
mice. All mice used in these experiments were bred and housed in a specific pathogen-free 
barrier facility. Mice were either maintained on chow diet or put on a pro-atherogenic high fat 
diet (15% FAT, 1.25% cholesterol) as mentioned in the figure legends.  
 
Flow cytometry and cell sorting assessment 
Total blood has been collected on heparin or EDTA tubes before counting and staining. Mice were 
perfused with PBS before organ removal. The spleen was dissociated and the bone marrow 
flushed. Cells were filtered and counted before staining. 
Blocking of non-specific binding of immunoglobulin to Fc receptors was done with a purified 
anti-mouse CD16/32 antibody. Leukocyte population was identified using the following 
antibodies: anti-CD11b (M1/70), anti-CD115 (AFS98), anti-Gr1 (RB6-8C5), anti-CD4 (RM4-5), 
anti-CD3 (145-2C11), anti-CD8 (53-6.7), anti-CD62L (MEL-14), Anti-CD44 (IM7) anti-B220 (RA3-
6B2) and anti-NK1.1 (PK136). Chemokines receptors were stained using an anti-CCR2 
(FAB5538P) and anti-CX3CR1 (SA011F11). We use anti-Bcl2 (Miltenyi Ref 130-105-430), anti-
Ki67 (BD Pharmingen Ref 556027) and anti-P38 MAP Kinase (Thr180/Tyr182-Cell signaling). 
For M1 and M2 markers, we used an anti-CD206 (C068C2) and anti-MHCII (M5/114.15.2). Blood 
samples were lysed with Red Blood Cells Lysing Buffer (Sigma-Aldrich, USA) and washed twice 
before analysis. All samples were analyzed on LSR Fortessa Analyser, and datas were obtained 
with the FlowJo Software. 
 
For cell sorting, the blood has been incubated with the following antibodies: anti-CD11b 
(M1/70), anti-Ly6C (AL-21), anti-Ly6G (1A8), anti-CD115 (AFS98), anti-CD19 (1D3), anti-CD4 
(RM4), anti-CD8 (53-6.7). Samples were lysed with Red Blood Cells Lysing Buffer (Sigma-Aldrich, 
USA) then washed and ressuspended in PBS 1X for analysis on ARIA II SORP CELL SORTER. 
Samples were collected apart on Qiazol Reagent (Qiagen, Deutchland) and frozen at -80°. 
 
mRNA analysis and real time qPCR 
RNA from high and low monocytes were isolated using the RNeasy MicroKit (Qiagen, 
Deutchland) according to the manufacturer’s instructions and frozen at -80°.  
For the miRNA reverse transcription, 5ng/μL of isolated RNA were used with the miRCURY™ 
LNA™ Universal RT microRNA PCR (Exiqon A/S, Denmark). Real time quantitative polymerase 
chain reaction was performed with SYBER GREEN reagent (Eurogentec), using miR-21-5p and 
miR-21-3p (Exiqon A/S, Denmark) primer. miR-21 expression was normalized to U6, 5S and 
RNU5G  (Exiqon A/S, Denmark) genes as references. Analysis was runned with ABI PRISM 
thermocycler. Relative expression was calculated using the 2-delta-delta CT method followed by 
geometric average, as recommended21. 
For the total mRNA reverse transcription, 100ng/μL of isolated RNA were used with the 
QuantiNova Reverse Transcription Kit (Qiagen, Deutchland). Real time quantitative polymerase 
chain reaction was operated with SYBER GREEN Reagent, using the following mouse primers: 
CX3CR1 5'-GGAGTCTGCGTGAGACTGGGTGAGTGA-3' and 5'-GAGGGCGTAGAAGACGGACAGGAAGATG-3', 
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Nur77 5'-GTCCTGGAGCCCGTGTCGATCA-3' and 5'-TTCCCGCCTTTGCCTGCCTGT-3', CCR2 5'-
GCCGTGGATGAACTGAGGTAACA-3' and 5'-GAGGGCATTGGATTCACCACA-3', CCR5 5'-
GGCAGGAGCTGAGCCGCAATTTGTTT-3' and 5'-GGTGAGACATCCGTTCCCCCTACAAGA-3', CXCR4 5’-
CTGAGGCGTTTGGTGCTCCGGTAA-3’ and 5’-ATCCCGGAAGCAGGGTTCCTTGT-3’. Relative expression of 
these genes were calculated using the ΔΔCT method, using the GAPDH 5'-
CGTCCCGTAGACAAAATGGTGAA-3' and 5'GCCGTGAGTGGAGTCATACTGGAACA-3' as reference gene. 
 
Bone marrow-derived macrophages and apoptosis assay in vitro 
Primary macrophages were derived from mouse bone marrow-derived cells (BMDM). Tibias and 
femurs of mice were dissected and their marrow flushed out. Cells were grown for 7 days at 37°C 
in a solution of RPMI 1640 medium, 20% neonatal calf serum, and 20% macrophage–colony- 
stimulating factor-rich L929-conditioned medium. To analyze apoptosis susceptibility, untreated 
BMDM were incubated with fetal calf serum- free medium, TNF- (10 g/ml) and cycloheximide 
(10 M), or etoposide (50 g/ml) for 12 hours.  Apoptosis was determined by using Annexin V 
fuorescein isothiocyanate apoptosis detection kit with 7-AAD (APC, BD Biosciences, San Jose, 
California) according to the manufacturer’s instructions. 
 
Dil+ liposome injection and monitoring of Ly-6Clo monocyte in vivo. 
Injection of Dil+ liposomes was used to address the role of miR-21 on the survival of NC-Mo in 
vivo. 200l of fluorescent Dil liposomes (Clodronate Liposome) were injected intraveneously to 
ApoE-/- and ApoE-/-miR21-/- to label NC-Mo. About 50% of NC-Mo were labeled after 24 hours in 
both groups. The turnover of labeled NC-Mo was determined by flow cytometry at days 1, 4, 7 
and 10 on 50l of blood samples. 
 
Bone marrow transplantation (BMT) 
For the competition assay 
 8-week-old male Apoe-/- CD45.2 mice were lethally irradiated (9.5 Gray) and intraveneously 
reconstituted with ten million cells coming from a 1:1 bone marrow cell mix of ApoE-/- CD45.1 
and ApoE-/- miR21-/- (or ApoE-/- miR21+/+ as control) CD45.2 medullar cells. Height weeks after 
reconstitution, blood samples were taken from mice maintained under isoflurane anesthesia to 
test the chimerism.  
For atherosclerosis quantification 
8 week-old male Apoe-/- mice were lethally irradiated (9.5 Gray) and intraveneously 
reconstituted with ten million cells coming from Apoe-/- or Apoe-/-miR-21-/- mice. Mice were kept 
on chow diet for 12 weeks post BMT or transitioned 4 weeks post BMT to a HFD for 10 weeks. 
 
Quantification of atherosclerotic lesions 
Mice were anesthetized with isoflurane before sacrifice. Plasma cholesterol was measured using 
a commercial kit (DiaSys® Cholesterol FS*, Germany). Quantification of lesion size and 
composition was performed as previously described22 and is in agreement with the recent 
recommendation23. Briefly, the heart and ascending aorta were removed, perfusion-fixed in situ 
with 4% paraformaldehyde, then placed in phosphate-buffered saline (PBS)-30% sucrose 
solution overnight, before being embedded in frozen optimal cutting temperature compound and 
frozen at -70°C. Afterwards, 10-mm serial sections of aortic sinus were obtained (cut on 
cryostat). Lipids were detected using Oil Red O (Sigma-Aldrich, St. Louis, Missouri) coloration 
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and quantified by a blinded operator using HistoLab software (Microvisions Instruments, Paris, 
France) 30, which was also used for morphometric studies. For lesion size quantification, 
multiple sections in multiple regions were analyzed. For tissue characteristics, same regions of 
the aortic sinus were used between animals. En face quantification was used for atherosclerotic 
plaques along thoraco-abdominal aorta, as previously described 22. 
Collagen was detected using Sirius red staining. The presence of macrophages was determined 
using monoclonal rat anti-mouse macrophage/monocyte antibody (MOMA)-2 (MAB1852). 
Apoptotic macrophages in the lesion were identified as MOMA-2+ TUNEL+ (Roche) or as cleaved-
caspase 3+ (5A1E). CD206 and MHCII stainings were done with anti-CD206 (C068C2) and anti-
MHCII (M5/114.15.2) antibodies. 
 
At least 4 sections per mouse were examined for each immunostaining, and appropriate negative 
controls were used. 
 
Monocyte labeling in vivo. NC-Mo were labeled in vivo by retro-orbital i.v. injection of 1 μm 
fluorescent microsphere (YG, Polysciences) diluted 1⁄4 in sterile PBS. Cell labeling was checked 
24 hours later by flow cytometry. The recruitment of bead+ labeled NC-Mo was quantified in the 
aorta, 5 days after labeling by counting the number of beads in the digested aorta, by flow 
cytometry. For staining on aortic cells, the aorta was removed and flushed intensively with 2 mM 
0,2% FBS PBS. The aorta was cut into pieces and digested using a cocktail of enzymes for 45 min 
at 37°C (450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml hyaluronidase I; all from 
Sigma-Aldrich). 
 
Thioglycollate assay 
Mice were injected intraperitoneally with 1 ml 3% thioglycollate. Peritoneal cells were harvested 
by successive lavages with cold PBS EDTA 0.5M. 
 
Efferocytosis assay in vivo 
5 males miR21+/+ and 5 males miR21-/- of 8 weeks were injected intraperitoneally with 2ml of 3% 
thioglycollate. 48 hours after, thymocytes from 4 weeks old C57Bl6 male mice were isolated, 
stained with CFSE (5M) for 5 minutes at 37 degrees. The reaction was stopped by adding cold 
fetal calf serum and washed twice with steril PBS. Apoptosis of thymocytes was induced by 
exposing the cells to UV radiation (0.25 Joule/minute) for 10 minutes. Apoptosis was controlled 
by flow cytometry (Annexin V-7AAD staining). Ten millions apoptotic thymocytes were injected 
intraperitoneally (1ml) to mice treated with thioglycollate. After 1 hour, we collected the 
peritoneal macrophages by lavage and immediately fixed the cells in PFA 4% to stop the 
efferocytosis process. Macrophages were stained with CD11b, F4/80 and analyzed by flow 
cytometry. Macrophages that had engulfed CFSE+ apoptotic thymocytes were identified as 
follow: CD11b+, F4/80+, CSFE+.  
 
Statistical analysis. 
Values are expressed as mean +/- SEM. Differences between values were evaluated using non-
parametric Mann-Whitney test, or other as specified in the legends. All these analyses were 
performed using GraphPad Prism version 5.0b for Mac (GraphPad Software) and values were 
considered significant at P<0.05. 
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Results  
 
miR-21 controls the maintenance and survival of NC-Mo in ApoE-/- mice 
We generated ApoE-/-miR-21-/- and ApoE-/-miR-21+/+ littermate controls. Under chow diet, plasma 
cholesterol levels were similar in the two groups (4.43 g/L 2.53 in ApoE-/-miR-21-/- mice versus 
4.11 g/L 1.02 in ApoE-/- mice, n=8-12/group). Likewise, the leukocyte populations in blood were 
mostly similar between the two groups, except for NC-Mo, which were decreased both in 
percentage and number, in the absence of miR-21 (Figure 1A and Figure I in the online-only Data 
Supplement). Similar observations were made in ApoE+/+ miR-21-/- mice supplemented with a 
HFD (Figure II in the online-only Data Supplement). The defect in NC-Mo in ApoE-/-miR-21-/- was 
seen in the spleen as well as in the bone marrow, revealing a general defect in NC-Mo production 
or maintenance (Figure IIIA and IIIB in the online-only Data Supplement). We therefore 
examined the expression level of miR-21 in circulating leukocytes. In ApoE-/- mice on chow diet, 
mir-21-5p was expressed at similar levels in monocytes, neutrophils, B and T cells (Figure IIIC in 
the online-only Data Supplement). Interestingly, its expression was 4-fold higher in NC-Mo 
compared to C-Mo (Figure 1B), suggesting that miR-21-5p might differently control the 
homeostasis of monocyte subsets. In contrast, miR-21-3p expression was bellow detection in all 
other circulating leukocyte subsets (not shown).  
We investigated the impact of miR-21 in monocyte subsets by exploring the expression of 
genes involved in cell survival and migration. In absence of miR-21, NC-Mo showed decreased 
Nr4a1 and Cx3cr1 mRNA expression (Figure 1C) and decreased CX3CR1 protein level (Figure IVA 
in the online-only Data Supplement). In contrast, there was no change in Ccr2 and Ccr5 
expression (Figure IVB in the online-only Data Supplement). We also observed a decrease in 
Ki67+ and BCL2+ NC-Mo in spleens of mice deficient for miR-21 (Figure 1D). miR-21 deficiency 
was associated with increased Phospho-P38 mitogen-activated protein kinase and decreased 
CD115 expression in circulating NC-Mo, but not in C-Mo (Figure 1D and Figure IVC in the online-
only Data Supplement). These phenotypic changes suggest that miR-21 may be acting as a 
survival and/or differentiation factor in NC-Mo by promoting expression of factors important for 
monocyte function. 
We therefore addressed the role of miR-21 on the homeostasis of NC-Mo in vivo. We pulse-
labeled circulating NC-Mo with Dil+ liposomes and quantified their rate of disappearance in 
blood. Injected Dil+ liposomes exclusively labeled NC-Mo (not shown). In control ApoE-/- mice, the 
level of Dil+NC-Mo decreased by 30% within 7 days. In contrast, ApoE-/-miR-21-/- labeled NC-Mo 
decreased by 70% within 7 days, showing a higher rate of disappearance from blood (Figure 1E). 
To complement this experiment, we designed a competitive congenic bone marrow (BM) 
transplant model, where irradiated ApoE-/-CD45.2 host mice were reconstituted with a 1:1 BM 
mix from ApoE-/-CD45.1 and ApoE-/-miR-21-/-CD45.2 (or control ApoE-/-CD45.2) donors, enabling 
the independent tracking of reconstituted haematopoietic cells from each donor (Figure 1F). 
After transplantation, we found similar amounts of CD45.1 and CD45.2 leukocytes in the control 
group, showing no bias in CD45.1 versus CD45.2 cell reconstitution. In contrast, we observed a 
significant failure in the reconstitution of miR-21-/-CD45.2 compared to CD45.1 cells in blood, 
revealing a bias in favor of miR-21 expressing cells. While the absence of miR-21 slightly affected 
every leukocyte subsets in blood, the proportion of miR-21-/- NC-Mo almost completely 
disappeared from the bloodstream (Figure 1F and Figure IVD in the online-only Data 
Supplement). These data confirmed that miR-21 deficiency controls monocyte subset ratios by 
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strongly impairing NC-Mo homeostasis in ApoE-/- mice, and revealed a more general effect of 
miR-21 on all leukocyte populations.  
 
miR-21 deficiency transiently delays the development of atherosclerosis in ApoE-/- mice  
 
We then explored the role of miR-21 at various stages of atherosclerosis development in ApoE-/- 
mice. In early atherosclerosis, at 10 weeks of age, the absence of miR-21 had no major impact on 
atherosclerosis lesion development or composition in ApoE-/- mice (Figure VA and VB in the 
online-only Data Supplement). At 24 weeks of age, the absence of miR-21 reduced atherosclerotic 
lesion size, both in the thoracic aorta and the aortic root (Figure 2A and 2B). In absence of miR-
21, macrophage content was unchanged (Figure 2C), but the amount of TUNEL+ apoptotic 
macrophages was increased in lesions (Figure 2D). At this stage, smooth muscle cell 
accumulation and necrotic area extent were not altered (not shown). In vitro, we found that the 
lack of miR-21 increased the susceptibility of macrophages to apoptosis (Figure VIA in the online-
only Data Supplement), which substantiates our in vivo data. In addition, we found that miR-21-/- 
macrophages became more inflammatory in plaques, as evidenced by the changes in CD206 and 
iNOS expression (Figure 2E). We confirmed that the absence of miR-21 broadly polarized 
macrophages to an M1-like signature (CD206- MHCIIhi) (Figure VIB in the online-only Data 
Supplement). We also examined the role of miR-21 on monocyte migration in vivo. C-Mo 
recruitment was tested in a model of sterile peritonitis in the mixed BM chimeras presented in 
Figure 1F. We found similar chimerism of monocytes/macrophages in the blood before and in the 
peritoneum after thioglycollate injection, suggesting that the absence of miR-21 had no impact on 
C-Mo trafficking in vivo (Figure VIIA in the online-only Data Supplement). The recruitment of NC-
Mo was quantified in the atherosclerotic aorta with a pulse-labeling method24. We found a 
decrease of bead+ NC-Mo in the aorta of mice deficient for miR-21 (Figure 2F), which could most 
likely be attributed to less NC-Mo in blood. Altogether, these data show that miR-21 deficiency 
decreases NC-Mo availability in blood, orientates plaque macrophages toward an inflammatory 
profile but increases their susceptibly to apoptosis. These concomitant events limit early 
atherosclerosis formation in ApoE-/-miR-21-/ - mice. 
We next analyzed the role of miR-21 in advanced atherosclerosis by feeding mice a HFD for 10 
weeks. miR-21-5p was expressed in all leukocyte subsets, independently of the diet. Again, its 
expression was increased in NC-Mo in comparison to C-Mo (Figure VIIB and VIIC in the online-
only Data Supplement). miR-21 absence decreased the numbers of circulating NC-Mo (Figure 
VIIIA in the online-only Data Supplement) while not affecting total cholesterol levels (not shown). 
Despite a conserved protection in the aorta (Figure VIIIB in the online-only Data Supplement), 
lesion size in the aortic root of ApoE-/-miR21-/- was similar to control ApoE-/- mice (Figure VIIIC in 
the online-only Data Supplement). Macrophage content did not change, but the necrotic core area 
was increased in mice deficient for miR-21 (Figure VIIID and VIIIE in the online-only Data 
Supplement). The amount of TUNEL+ apoptotic macrophages in lesions was increased and 
similar data were obtained using activated caspase-3 as an assay for lesional apoptosis (Figure 
IXA in the online-only Data Supplement). Neutral lipid and collagen contents were unchanged 
(Figure IXB in the online-only Data Supplement). Because necrotic core development likely 
occurs through the combination of defective efferocytosis and enhanced macrophage death, we 
examined the role of miR-21 on efferocytosis in vivo. The absence of miR-21 decreased by almost 
2 fold the capacity of peritoneal macrophages to engulf CFSE-labelled apoptotic thymocytes 
(Figure 2G), in agreement with recent findings18.  
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We additionally examined the specific contribution of myeloid-derived miR-21 in atherosclerosis 
development by performing bone marrow transplantations (BMT). The absence of miR-21 in the 
hematopoietic compartment reduced plaque size when mice were kept on chow diet for 12 
weeks after BMT (Figure 2H), but had no effect when mice were fed a HFD for 10 weeks after 
BMT (Figure XA in the online-only Data Supplement). As expected, the level of blood NC-Mo was 
decreased (Figure XB in the online-only Data Supplement). These results strengthen our 
conclusion that miR-21 deficiency impacts NC-Mo homeostasis, which at least in part contributes 
to limit early-stage atherosclerosis. 
 
  
Discussion  
 
The purpose of this study was to investigate the role of miR-21 in homeostasis of monocytes in 
ApoE-/- mice. RNA-based therapeutics have demonstrated great promise for the treatment of 
different diseases and miR-21 is an interesting target as it regulates macrophage polarization, 
apoptosis and efferocytosis15. Here, we report for the first time that miR-21 expression is 
increased in circulating NC-Mo from ApoE-/- mice on chow or high fat diet, compared to C-Mo. 
miR-21 deficiency in ApoE-/- mice significantly altered the amount of circulating NC-Mo, which 
could be accounted for by decreased NC-Mo longevity as shown by our in vivo experiments. We 
analyzed the role of miR-21 on atherosclerosis development in ApoE-/- mice, at 3 different stages 
of the disease. miR-21 deficiency partially protected against early development of atherosclerosis 
(at 10 and 24 weeks of age), despite the tendency of plaque macrophages to be more 
inflammatory and more susceptible to apoptosis. In contrast, at later stages of atherosclerosis 
(after 10 weeks on HFD), lesion size in the aortic root was similar in ApoE-/- and ApoE-/-miR-21-/- 
mice, but less stable (larger necrotic core) in the latter. Using BMT, we found that the protection 
conferred in absence of miR-21, in early atherosclerosis, was related to the hematopoietic 
compartment. Our interpretation is that the absence of miR-21, concomitant limitation of 
monocyte-derived macrophage influx in the forming lesion and increased apoptosis of local 
macrophages protected against early atherosclerosis formation. The loss of protection in more 
advanced stages is most likely due to excessive inflammatory apoptosis due to impaired 
efferocytosis, and to a possible minor recruitment of NC-Mo in lesions under conditions of 
prolonged HFD. In a recent study using BMT, Canfran-Duque et al. found that miR21 deficiency in 
hematopoietic cells accelerated atherosclerosis via increased apoptosis and decreased 
efferocytosis of plaque macrophages17 in LDLr-/- mice under HFD during 12 weeks. Our results in 
ApoE-/- mice under HFD are mostly in line with those results. The reason why we observed a 
protection against early atherosclerosis might be due to the decreased level of circulating NC-Mo 
observed in our model, which likely limited the early accumulation of macrophages in the plaque 
and therefore delayed the inflammatory effect of unbalanced apoptosis/efferocytosis in the 
absence of miR21. Surprisingly, a more recent study reported increased lesion size in the thoracic 
aorta of miR-21-/- ApoE-/- mice on chow diet 20, which contrasts with our present findings. One 
unexplained result from that study20 is that 16 week-old ApoE-/- mice had no detectable 
atherosclerotic lesions in the thoracic aorta.  
Our observation that miR-21 controls the survival of NC-Mo are important for several reasons. 
First, considering that monocyte subsets are committed to divergent functions, there is a need to 
identify specific factors that regulate the balance between C-Mo and NC-Mo in pathophysiological 
conditions. Recently, miR-146a was identified as a specific regulator of C-Mo responses during 
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inflammatory challenges, without NC-Mo modifications25. Targeting miR-146 and miR-21 may 
then serve to limit the expansion and function of selective monocyte subsets. Second, human 
studies have underscored the relevance of studying monocyte subsets because an imbalance in 
their relative proportion is linked to several diseases26. For instance, increased proportions of 
NC-Mo have been reported in patients with inflammatory conditions, including sepsis and 
rheumatoid arthritis27-29. In atherosclerosis, the function, as well as time course and spatial 
distribution of NC-Mo are still unclear. In a previous study in ApoE-/- mice on chow diet for 25 
weeks, we found that NC-Mo may significantly contribute to lesion formation, at least under 
moderate hypercholesterolemia1. Our current work in ApoE-/- mice on chow and high fat diet 
supports this finding. A recent study suggested an anti-atherogenic role of NC-Mo under massive 
hypercholesterolemia, in ldlr-/- mice under HFD for 15 weeks8. The properties and functions of 
NC-Mo may then differ according to the experimental settings and may account for the 
discrepancies between our work and that of Canfran-Duque et al17.  
The fact that miR-21 expression increases in NC-Mo could explain their longer longevity as 
compared to C-Mo. The mechanisms whereby miR-21 regulates the cell death effector pathways 
in NC-Mo and whether hypercholesterolemia dictates the longevity of NC-Mo through the 
increase of miR-21 expression need further investigation. We did not find any effect of miR-21 
deficiency on monocyte migration despite the decrease in CX3CR1 expression. We cannot exclude 
a role of miR-21 on NC-Mo patrolling in large arteries, even though this property was shown to 
be CX3CR1 independent7, 8. It is also unlikely that miR-21 deficiency has altered NC-Mo 
production as it is now well accepted that NC-Mo mon cytes derive directly from the C-Mo30,31, 32. 
Yet, we cannot rule out the possibility that the conversion of C-Mo into NC-Mo in blood was 
partially altered since C-Mo count in blood was unchanged despite a reduction of C-Mo in the 
bone marrow. Finally, we have not addressed the potential contribution of miR-21 to 
atherosclerosis through other cell types, particula ly T lymphocyte activation33 and smooth 
muscle cell proliferation 20, 34. 
 
In summary, the data herein shed light on a previously unknown role of miR-21 in the 
homeostasis of NC-Mo in ApoE-/- mice and brings new evidence on the role of miR-21 in 
atherosclerosis development.  
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Highlights 
- miR-21 expression is high in circulating Ly-6Clo monocytes  
- The absence of miR-21 alters the survival and number of circulating Ly-6Clo monocytes in 
mice 
- miR-21 deficiency partially protects ApoE-/- mice from early but not advanced 
atherosclerotic plaque formation 
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Figure legends  
Figure 1: miR-21 controls the survival of non-classical monocytes in ApoE-/- mice  
A- Percentage and numbers of blood monocyte subsets in ApoE-/- and ApoE-/-miR-21-/- mice (flow 
cytometry, n=8 per group). B- miR-21-5p expression in blood monocyte subsets. C- NR4A1 and 
CX3CR1 mRNA in blood monocyte subsets (n=4-10 per group). D- Amount of Ki67+, BCL-2+ and 
Phospho-P38 MAPK+ in NC-Mo in mice (n=4 per group). E- Monitoring of NC-Mo survival after 
labeling with DIL+ liposomes in ApoE-/- and ApoE-/-miR-21-/- mice in vivo. F- Experimental design 
of the chimera experiment (left). Relative proportions of circulating CD45.1 and CD45.2 cells 8 
weeks following mixed bone marrow transplantation (right). N=8-9 per group. Mann Whitney 
non-parametric test was used. P0.05, P0.01, P0.001.  
 
 
Figure 2: miR-21 deficiency decreases the development of early atherosclerosis in ApoE-/- 
mice  
A-D Atherosclerosis quantification in ApoE-/- and ApoE-/-miR-21-/- mice on chow diet for 24 
weeks. A- Plaque size in the aorta and B- the aortic root. C- Macrophage (MOMA2 staining) and 
D- apoptotic macrophage (TUNEL+) quantification in lesions. E Quantification of 
immunofluorescent staining of MOMA2 and CD206 as markers of M2 macrophages (left), and 
MOMA2 and iNOS as markers of M1 macrophages in lesions (right). F- Analysis of the 
recruitment of NC-Mo in the aorta of ApoE-/- and ApoE-/-miR-21-/- mice. Fluorescent green beads 
were intravenously injected to label circulating Ly-6Clo monocytes, seven days before flow 
cytometry analysis on digested aortas. G- Efferocytosis of CFSE-labeled apoptotic thymocytes by 
macrophages in peritoneum of miR-21-/- or miR-21+/+ mice in vivo. Gates were set using mice that 
did not receive CFSE-labeled cells. Representative FACS plots are shown for the 2 groups. H- 
Quantification of plaque size in the aortic sinus of mice on chow diet for 12 weeks after bone 
marrow transplantation. Mann Whitney non-parametric test was used throughout. P0.05, 
P0.01. 
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Supplemental	figure	I	
Flow	cytometry	analysis	of	blood	leukocyte	subsets	(Left:	percentages,	right:	cell	numbers)	from	ApoE-/-	and	ApoE-/-
miR-21-/-	 mice	 on	 chow	 diet.	 Statistical	 significance	 was	 calculated	 using	 a	 Mann	Whitney	 non-parametric	 test.	
¬P<0.05,	¬¬P<0.01,	¬¬¬P<0.001				
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Supplemental	figure	II	
Flow	cytometry	analysis	of	blood	leukocyte	subsets	(Left:	percentages,	right:	cell	numbers	n=5-10	per	group)	from	miR-21+/+	and	
miR-21-/-	 mice	 on	 chow	 diet	 or	 high	 fat	 diet	 for	 2	 weeks.	 Statistical	 significance	 was	 calculated	 using	 a	 Mann	Whitney	 non-
parametric	test.	¬P<0.05,	¬¬P<0.01,	¬¬¬P<0.001	
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Supplemental	figure	III	
A,B-	 Flow	 cytometry	 analysis	 of	 leukocyte	 subsets	 in	 spleen	 (A)	 and	 bone	marrow	 (B)	
from	ApoE-/-	and	ApoE-/-miR-21-/-	mice	on	chow	diet.	Statistical	significance	was	calculated	
using	 a	 Mann	 Whitney	 non-parametric	 test.	 ¬P<0.05,	 ¬¬P<0.01,	 ¬¬¬P<0.001	 C-	
miR-21-5p	expression	in	blood	leukocyte	subsets	from	ApoE-/-	mice	on	chow	diet	(n=3	per	
group).	Unpaired	two-sided	Student’s	t-	test.	
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Supplemental	figure	IV	
A-	Mean	fluorescence	intensity	of	CX3CR1	on	splenic	NC-Mo.	B-	Ccr5	and	Ccr2	gene	expression	in	cell	sorted	C-Mo	and	NC-Mo	from	blood	of	
ApoE-/-	and	ApoE-/-miR-21-/-	mice	(n=4-10	per	group).	Representative	gating	strategy	(Left)	C-	Phospho-P38	MAPK	and	CD115	expression	as	
percentages	or	MFI	in	monocyte	subsets.	D-Quantification	of	leukocyte	subsets	in	the	blood	of	chimeric	mice	8	weeks	after	transplantation,	
by	 flow	 cytometry.	 N=8-9	 per	 group.	 Statistical	 significance	 was	 calculated	 using	 a	 Mann	 Whitney	 non-parametric	 test.	 ¬P<0.05,	
¬¬P<0.01¬¬¬P<0.001.		
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Supplemental	figure	V	
A-	Quantification	of	plaque	size	 in	the	aortic	sinus	and	 in	the	aorta	of	ApoE-/-	and	ApoE-/-miR-21-/-	on	chow	diet	 for	10	weeks.	B-	
Quantification	 of	 macrophage	 (MOMA2	 staining),	 T	 cell	 (CD3	 staining)	 and	 collagen	 (Sirius	 Red	 coloration)	 accumulation	 per	
sections	of	the	aortic	sinus.	Mann	Whitney	non-parametric	test	was	used.	¬P<0.05.			
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Supplemental	figure	VI	
A-Flow	cytometric	analysis	of	apoptotic	BMDM	from	ApoE-/-	and	ApoE-/-miR-21-/-	mice	after	exposure	to	indicated	pro-apoptotic	mediators.	
Unpaired	t-test	was	used.	¬P<0.05,	¬¬P<0.01,	¬¬¬P<0.001.			
B-	Quantification	of	M1	and	M2	macrophages	isolated	from	the	inflamed	peritoneum	after	48	of	thioglycollate	in	miR-21+/+	and	miR-21-/-	
mice	on	chow	or	on	HFD	for	two	weeks	(flow	cytometry,	n=5	per	group).	Mann	Whitney	non-parametric	test.	¬P<0.05,	¬¬P<0.01.		
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Supplemental	figure	VII	
A-	C-Mo	migration	was	evaluated	in	sterile	peritonitis	in	mixed	chimera	mice	(Experimental	design	as	in	Fig1G).	The	chimerism	of	C-Mo	was	
tested	in	both	groups	in	blood	before	thioglycollate	injection.	Five	days	after	thioglycollate	injection,	the	relative	proportions	of	CD45.1	and	
CD45.2	monocyte-derived	macrophages	was	quantified	 in	 the	peritoneal	 cavity.	N=4-5	per	group.	B-	miR-21-5p	expression	 in	 circulating	
leukocyte	subsets	from	ApoE-/-	mice	on	chow	diet	(as	in	Supl	fig	3C)	or	high	fat	diet	for	2	weeks	(n=4	per	group).	C-	miR-21-5p	expression	in	
blood	monocyte	subsets	from	ApoE-/-		mice	on	chow	or	high	fat	diet		for	2	weeks	(n=8	per	group)	
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Supplemental	figure	VIII	
A-	Analysis	of	monocyte	subset	amount	and	number	in	ApoE-/-	and	ApoE-/-miR-21-/-	mice	under	HFD	for	10	weeks	(n=5/
group)B-C	Atherosclerosis	quantification	in	mice	on	HFD	for	10	weeks.	B-	Plaque	size	in	the	aorta	and	C-	in	the	aortic	
root.	D-	Quantification	of	macrophage	accumulation	and	E-	necrotic	core	area	in	lesions	of	the	2	groups.	Statistical	
significance	was	calculated	using	a	Mann	Whitney	non-parametric	test.	¬P<0.05,	¬¬P<0.01.	
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Supplemental	figure	IX	
ApoE-/-	and	ApoE-/-miR-21-/-	mice	under	HFD	for	10	weeks	A-	Quantification	of	
apoptotic	macrophages	with	TUNEL	and	cleaved-caspase	3	stainings	in	plaques.	
B-	Quantification	of	lipid+	(Oil	Red	O+	area)	and	collagen+	(Sirius	Red+)	areas	
within	the	lesions	in	the	aortic	sinus	of	mice.	Statistical	significance	was	
calculated	using	a	Mann	Whitney	non-parametric	test.	¬P<0.05.	
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Supplemental	figure	X		
A-	Quantification	of	plaque	 size	 in	 the	aortic	 sinus	of	mice	on	HFD	 for	10	weeks	
after	BMT	B-	Monocyte	susbets	 in	blood	of	mice.	Mann	Whitney	non-parametric	
test	was	used.	¬P<0.05.		
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